These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
385 related articles for article (PubMed ID: 28382573)
1. Serum global metabolomics profiling reveals profound metabolic impairments in patients with MPS IIIA and MPS IIIB. Fu H; Meadows AS; Pineda RJ; Mohney RP; Stirdivant S; McCarty DM Metab Brain Dis; 2017 Oct; 32(5):1403-1415. PubMed ID: 28382573 [TBL] [Abstract][Full Text] [Related]
2. Near-Complete Correction of Profound Metabolomic Impairments Corresponding to Functional Benefit in MPS IIIB Mice after IV rAAV9-hNAGLU Gene Delivery. Fu H; Meadows AS; Ware T; Mohney RP; McCarty DM Mol Ther; 2017 Mar; 25(3):792-802. PubMed ID: 28143737 [TBL] [Abstract][Full Text] [Related]
3. Unveiling metabolic remodeling in mucopolysaccharidosis type III through integrative metabolomics and pathway analysis. Tebani A; Abily-Donval L; Schmitz-Afonso I; Héron B; Piraud M; Ausseil J; Zerimech F; Gonzalez B; Marret S; Afonso C; Bekri S J Transl Med; 2018 Sep; 16(1):248. PubMed ID: 30180851 [TBL] [Abstract][Full Text] [Related]
4. Targeted Metabolomic Analysis of a Mucopolysaccharidosis IIIB Mouse Model Reveals an Imbalance of Branched-Chain Amino Acid and Fatty Acid Metabolism. De Pasquale V; Caterino M; Costanzo M; Fedele R; Ruoppolo M; Pavone LM Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32545699 [TBL] [Abstract][Full Text] [Related]
5. Urinary metabolic phenotyping of mucopolysaccharidosis type I combining untargeted and targeted strategies with data modeling. Tebani A; Schmitz-Afonso I; Abily-Donval L; Héron B; Piraud M; Ausseil J; Brassier A; De Lonlay P; Zerimech F; Vaz FM; Gonzalez BJ; Marret S; Afonso C; Bekri S Clin Chim Acta; 2017 Dec; 475():7-14. PubMed ID: 28982054 [TBL] [Abstract][Full Text] [Related]
6. Analysis of Mucopolysaccharidosis Type VI through Integrative Functional Metabolomics. Tebani A; Abily-Donval L; Schmitz-Afonso I; Piraud M; Ausseil J; Zerimech F; Pilon C; Pereira T; Marret S; Afonso C; Bekri S Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30669586 [TBL] [Abstract][Full Text] [Related]
7. Glycosaminoglycans and mucopolysaccharidosis type III. Jakobkiewicz-Banecka J; Gabig-Ciminska M; Kloska A; Malinowska M; Piotrowska E; Banecka-Majkutewicz Z; Banecki B; Wegrzyn A; Wegrzyn G Front Biosci (Landmark Ed); 2016 Jun; 21(7):1393-409. PubMed ID: 27100513 [TBL] [Abstract][Full Text] [Related]
8. Effects of Trehalose Administration in Patients with Mucopolysaccharidosis Type III. Mobini M; Radbakhsh S; Kubaski F; Eshraghi P; Vakili S; Vakili R; Abbasifard M; Jamialahmadi T; Rajabi O; Emami SA; Tayarani-Najaran Z; Rizzo M; Eid AH; Banach M; Sahebkar A Curr Med Chem; 2024; 31(20):3033-3042. PubMed ID: 37038706 [TBL] [Abstract][Full Text] [Related]
9. Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB. Wilkinson FL; Holley RJ; Langford-Smith KJ; Badrinath S; Liao A; Langford-Smith A; Cooper JD; Jones SA; Wraith JE; Wynn RF; Merry CL; Bigger BW PLoS One; 2012; 7(4):e35787. PubMed ID: 22558223 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of heparin cofactor II-thrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB mice. Langford-Smith K; Arasaradnam M; Wraith JE; Wynn R; Bigger BW Mol Genet Metab; 2010 Mar; 99(3):269-74. PubMed ID: 19926322 [TBL] [Abstract][Full Text] [Related]
11. Neuroinflammatory and oxidative stress phenomena in MPS IIIA mouse model: the positive effect of long-term aspirin treatment. Arfi A; Richard M; Gandolphe C; Bonnefont-Rousselot D; Thérond P; Scherman D Mol Genet Metab; 2011 May; 103(1):18-25. PubMed ID: 21353610 [TBL] [Abstract][Full Text] [Related]
12. Longitudinal MRI brain volume changes over one year in children with mucopolysaccharidosis types IIIA and IIIB. Abreu NJ; Selvaraj B; Truxal KV; Moore-Clingenpeel M; Zumberge NA; McNally KA; McBride KL; Ho ML; Flanigan KM Mol Genet Metab; 2021 Jun; 133(2):193-200. PubMed ID: 33962822 [TBL] [Abstract][Full Text] [Related]
16. Peripheral nervous system neuropathology and progressive sensory impairments in a mouse model of Mucopolysaccharidosis IIIB. Fu H; Bartz JD; Stephens RL; McCarty DM PLoS One; 2012; 7(9):e45992. PubMed ID: 23049915 [TBL] [Abstract][Full Text] [Related]
17. Accelerated clinical disease and pathology in mucopolysaccharidosis type IIIB and GalNAc transferase double knockout mice. Mohammed EE; Snella EM; Rutz-Mendicino MM; Echevarria FD; Awedikian R; Whitley EM; Ellinwood NM Mol Genet Metab; 2012 Sep; 107(1-2):129-35. PubMed ID: 22867887 [TBL] [Abstract][Full Text] [Related]
18. Differential distribution of heparan sulfate glycoforms and elevated expression of heparan sulfate biosynthetic enzyme genes in the brain of mucopolysaccharidosis IIIB mice. McCarty DM; DiRosario J; Gulaid K; Killedar S; Oosterhof A; van Kuppevelt TH; Martin PT; Fu H Metab Brain Dis; 2011 Mar; 26(1):9-19. PubMed ID: 21225451 [TBL] [Abstract][Full Text] [Related]
19. Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA. Roberts AL; Rees MH; Klebe S; Fletcher JM; Byers S Mol Genet Metab; 2007; 92(1-2):115-21. PubMed ID: 17681480 [TBL] [Abstract][Full Text] [Related]